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EBOLA VIRUS DISEASE: AN UPDATE ON CURRENT PREVENTION AND 1 
MANAGEMENT STRATEGIES 2 
 3 
Abstract 4 
Ebola virus disease (EVD) is characterised by systemic viral replication, immuno-5 
suppression, abnormal inflammatory responses, large volume fluid and electrolyte 6 
losses, and high mortality in under-resourced settings. There are various therapeutic 7 
strategies targeting EVD including vaccines utilizing different antigen delivery 8 
methods, antibody-based therapies and antiviral drugs. These therapies remain 9 
experimental, but received attention following their use particularly in cases treated 10 
outside West Africa during the 2014-15 outbreak, in which 20 (80%) out of 25 11 
patients survived. Emerging data from current trials look promising and are 12 
undergoing further study, however optimised supportive care remains the key to 13 
reducing mortality from EVD. 14 
    15 
1.0 Introduction: 16 
Based on minor variations in genomic sequences and the regions where first 17 
identified, Ebola viruses are classified into five species: Zaire ebolavirus 18 
(EBOV), Sudan ebolavirus (SUDV), Bundibugyo ebolavirus (BDBV), Taï  19 
Forest ebolavirus (TAFV), and the only Asian species Reston ebolavirus 20 
(RESTV).[1] The first three of these have previously caused large outbreaks 21 
in the Democratic Republic of Congo, Sudan, Gabon, Republic of Congo, and 22 
Uganda.[2] The most recent and largest outbreak involving over 28,000 cases 23 
in West Africa was caused by a variant strain of EBOV with an estimated 24 
overall case fatality rate of around 40%.[3] 25 
EVD is primarily a diarrheal illness that requires copious amounts of fluid and 26 




to mortality and thus an intensive level of support is required to optimize 28 
outcomes. This is challenging in resource limited settings.  29 
There were no approved therapeutics to treat Ebola virus disease (EVD) 30 
during the 2014-15 outbreak, that devastated three West African countries.[5] 31 
A small number of cases were treated with putative therapeutics in the U.S 32 
and Europe before formalised clinical trials were established late in the 33 
outbreak.[6] Potentially, an effective therapeutic available in large quantities 34 
could not only treat individual cases but halt outbreaks.  35 
1.1 Practicalities of clinical trials for Ebola virus disease 36 
Although a number of experimental vaccines and antivirals against Ebola 37 
virus had been developed prior to the large EVD outbreak in West Africa in 38 
2014-15, phase II/III field studies did not get underway until late in the 39 
epidemic.[6] Consequently, some studies will now have insufficient 40 
recruitment to establish efficacy.[40] This highlights the unique difficulties 41 
encountered in conducting clinical trials in the midst of a health emergency, 42 
particularly in resource poor settings. Nevertheless, for a disease such as 43 
EVD, which has such a high mortality and no proven directed therapy, it is 44 
imperative that an integral part of the international response be to facilitate 45 
clinical trials of therapeutic agents.  46 
International agencies setting up treatment centres must be willing to recruit 47 
patients into clinical trials, and have structures in place to manage the ethical 48 
and medico-legal requirements to facilitate their conduct.[6] Ethical 49 
considerations around the design of clinical trials in such settings can be 50 




are not ideal as they may lead to withholding of potentially beneficial 52 
treatment (albeit experimental) from those with a condition that otherwise has 53 
a very poor outcome.[6] Using historical controls can circumvent this issue, 54 
but calls into question the robustness of the study outcomes. Adaptive trial 55 
designs where ongoing planned interim monitoring of the outcome data can 56 
be used to alter the trial design after commencement to maximize the 57 
potential benefit to study participants while maintaining statistical reliability, 58 
have also been advocated for such studies.[55] Other challenges to 59 
conducting clinical trials in such settings are the need for study personnel to 60 
enter the “red zone” of Ebola treatment centres (ETCs) to consent patients, 61 
thereby risking exposure to Ebola themselves, obtaining consent from very 62 
unwell patients for complex studies when next of kin are unable to be present 63 
at the bedside, and co-ordinating and expediting the ethical review process 64 
between multiple governmental and non-governmental healthcare 65 
organisations and research institutions. [55] Consent procedures can be 66 
further complicated by the cultural and linguistic barriers. 67 
This paper will review proposed therapeutics (including vaccines, antibody 68 
based therapies, and small molecules) – many of which have only been 69 
tested in vivo on rodents or non-human primates (NHPs).[2]    70 
 71 
2.0 Vaccines against Ebola virus disease: 72 
Vaccines are a potential cornerstone for limiting or fully preventing an EVD 73 
outbreak. There are numerous vaccine trials including two leading candidates 74 




stomatitis virus vector) and ChAd3-ZEBOV (adenovirus vector).[7,8] Other 76 
potential candidates have been described elsewhere.[9] 77 
2.1 Recombinant vesicular stomatitis virus vector vaccines: 78 
When vesicular stomatitis virus was used in antigen delivery in NHPs, 50% 79 
protection was observed which was still effective up to thirty minutes post 80 
acquiring infection.[7] Recently, the interim results of a cluster randomized 81 
phase III trial of rVSV-EBOV in Guinea have been published.[10] The difficult 82 
logistics of conducting such a trial were mitigated effectively by a ring 83 
vaccination strategy, where adult contacts and contacts of contacts of patients 84 
with EVD were included. Clusters of participants were randomized 1:1 into 85 
immediate versus delayed (21 days) vaccination. Out of 2014 participants 86 
from 48 clusters in the immediate group, there were no EVD cases after 10 87 
days post vaccination, compared to 16 cases occurring in the delayed group 88 
of 2380 participants allocated to 42 clusters. Only one case had a febrile 89 
illness associated with the vaccine, which resolved without sequelae. 90 
Although the study did not provide measures of antibody titres, it concluded 91 
that it might take up to 6 days for the vaccine to provide protection.   92 
Prior phase 1 trials of rVSV-EBOV vaccine, including patients from various 93 
sites in the U.S, Africa and Europe, found a high number of adverse events in 94 
90% of the study population.[11,12] The majority of events were reported as 95 
mild or moderate, appeared and subsided early (<24 hours), and were 96 
alleviated with simple analgesics. Rapid onset and transient haematological 97 
changes were observed in all participants including transient leukocytopenia 98 




glycoprotein specific antibodies, although it could not be concluded whether 100 
higher vaccine doses would be required for optimal protection.  101 
Two further attenuated forms of rVSV: rVSVN4CT1GP1 and rVSVN1CT1GP3 102 
were studied by Mire et al [13], following concerns of developing arthritis in 103 
some participants in prior trials [11]. None of the vaccinated experimental 104 
animals (n=8) showed any signs of severe illness when exposed to lethal 105 
challenge of EBOV.  106 
The advantages of the rVSV vaccine platforms include a shorter time to 107 
achieve protecting antibodies by inducing humoral immunity which is key to 108 
survival in experimental subjects.[8,14] This renders them favorable in 109 
outbreak settings. The relatively low pre-existing immunity to VSV in various 110 
populations is an added value.[15] Duration of protective immunity, however, 111 
remains unknown. 112 
2.2 Adenovirus vector vaccines: 113 
To date there are no published phase III trials describing adenovirus vector 114 
vaccines. In a phase 1 double-blinded, placebo controlled trial of an 115 
adenovirus type-5 vector-based Ebola vaccine conducted in China [16], 120 116 
adults received a vaccine matching the glycoprotein of the 2014 EBOV. The 117 
study demonstrated significant increase in Glycoprotein-specific antibody 118 
titres at both day 14 and day 28 (p<0·0001) and the treatment was well 119 
tolerated. The generalisability of this study however is limited given the 120 
variable prevalence of baseline adenovirus type-5 neutralising antibody in 121 




There are concerns regarding adenovirus- linked vaccination given previous 123 
failures in HIV trials, which were stopped early.[17] The vaccine may reduce 124 
suppressive regulatory cells.[18] As such, given high rates of HIV prevalence 125 
in Africa, if vaccination was to continue with an adenovirus vector vaccine, it 126 
has been suggested that HIV education and prophylaxis should be included in 127 
the vaccination regimen.[19]  128 
In comparison to rVSV-EBOV, ChAd3-EBOV vaccines strongly induce cellular 129 
immunogenicity, which could provide longer duration of vaccine efficacy.[20] 130 
ChAd3-EBOV can potentially be boosted by a modified vaccinia Ankara 131 
(MVA) strain to produce higher and longer lasting antibody titres. [21]  This 132 
advantage favours their use in pre-outbreak settings or in health care workers.  133 
2.3 Vaccine use post exposure to Ebola Virus: 134 
Following needle stick injury, rVSV-ZEBOV vaccine has been used in a 44 135 
year old US physician caring for patients in an Ebola treatment unit in Sierra 136 
Leone.[22] Forty-three hours after exposure the vaccine was administered 137 
and the patient evacuated to the US. Similar to a previous case where 138 
vaccination was administered after laboratory exposure,[23] The patient had a 139 
clinical syndrome consistent with vaccination response. He developed 140 
antibodies to Ebola virus glycoprotein (a vaccine component), but not to Ebola 141 
virus VP40, which would be indicative of natural infection.  142 
2.4 Other Antigen and vaccine delivery methods: 143 
Cytomegalovirus (CMV) based vaccination has also been studied in 144 
rodents.[24] A single dose of CMV expressing a CD8 T cell epitope from 145 




durable CD8+T cell immunity for at least 33 weeks. No EBOV disease was 147 
observed in vaccinated mice when challenged. These mice did however show 148 
loss of weight, suggesting protection may be only partial.  149 
The intranasal route has also been suggested as a potentially effective 150 
vaccine delivery method.[25] This method has the potential to increase 151 
acceptance, especially in populations distrustful of Western medicine. 152 
Intranasal vaccines target the mucosal sites at which Ebola is contracted, 153 
minimise the need for specialised health care workers in resource deplete 154 
settings and reduce cost. They also decrease storage requirements, minimise 155 
medical waste and reduce the need for populations to travel to be vaccinated. 156 
3.0 Antibody based therapies: 157 
Human survivors of EBOV tend to mount early, vigorous, and long standing 158 
neutralizing antibodies (NAbs) that can bind to EBOV structural envelop 159 
glycoprotein (GP).[52] Identification of such NAbs and their mechanism of 160 
activity has been essential in the development of immunotherapies and 161 
vaccines against EBOV. The breadth of protection of such NAbs is variable 162 
and still undergoing study.[53] 163 
 164 
3.1 Convalescent Blood Products 165 
Convalescent blood products have been used during Ebola outbreaks under 166 
the pretext that they contain NAbs against EBOV.[26] In one of the earliest 167 
landmark studies, from the Kikwit outbreak in 1995, whole blood transfusions 168 
were donated by five convalescent patients, to eight patients with EVD. Five 169 




day 4 after receiving their transfusions. The mortality rate for this patient 171 
group was 12.5% (1 in 8), which was smaller than the 80% overall mortality 172 
for the outbreak. Whether these results can be generalized is unknown, as the 173 
study was limited by its small number of patients and lack of controls. 174 
Additionally, the intervention was undertaken during the late phase of the 175 
epidemic when health resources were greatly improved. There have also 176 
been suggestions that at the end of an EBOV epidemic, the virus may 177 
become less infectious and less virulent.[27]  A more recent, larger, and better 178 
designed study that included 99 patients from Guinea did not show a 179 
statistically significant survival benefit in receiving up to 500 ml of 180 
convalescent plasma.[28] Paediatric patients younger than 5 years of age 181 
appeared to benefit from the transfusions, however a conclusion could not be 182 
made due to the low numbers. The study was conducted towards the end of 183 
the outbreak, when mortality rates were less than 20%. Due to logistics, the 184 
convalescent plasma NAbs levels were not tested, but this reflected real life 185 
settings. It has been suggested that convalescent blood products after 9 186 
months from recovery might contain higher levels of NAbs and hence be more 187 
protective.[29] At least 8 patients treated outside Africa have reportedly 188 
received convalescent serum, 7 of whom survived. [3,41-5]  189 
3.2 Monoclonal antibody combinations (ZMapp, MB-003, and ZMab) 190 
A single antibody may not be able to neutralize every single viral particle, and 191 
hence a cocktail of antibodies may be required. Neutralising antibodies from 192 
convalescent blood can be produced in vitro in the form of cocktails of 193 
monoclonal antibodies (mAbs) against EBOV glycoprotein (GP). For example, 194 




cocktail of mouse mAbs (m1H3, m2G4, m4G7), and MB003 a cocktail of 196 
human-mouse chimeric mAbs (c13C6, h13F6, c6D8) (Table-1). Four out of six 197 
patients treated outside Africa have reportedly received ZMapp and survived. 198 
[3,41-5] Details of those therapies, including timing and doses of serum or 199 
antibody cocktails remain unpublished.  Compared to vaccines that require 200 
longer time to induce protection, antibody-based-therapies can potentially 201 
offer protection immediately after EBOV exposure for up to 120 hours in 202 
animal models [30] (Table-1).  Their major drawbacks however are a lack of 203 
availability and a significantly declining efficacy when given later in the course 204 
of experimental infection.  205 
Qiu et al. investigated the administration of ZMAb.[31] All four NHPs (100%) 206 
receiving the cocktail at 24 hours post EBOV challenge survived whilst two 207 
(50%) survived in the 48-hour group. Of note one of the non-survivors carried 208 
an escape mutant with mutations in EBOV-GP (amino acids 275 and 508). 209 
EBOV-GP IgM and IgG were present up till day 28. ZMAb half-life is still 210 
unknown and as such timing of treatment and dosing still require further 211 
investigation. Two patients with EVD in the latest outbreak in Sierra Leone, 212 
who were treated in Europe, received ZMAb and survived. [45, 56] 213 
In a previous study utilizing NHPs, co-administration of mAb and adenovirus-214 
vectored interferon-a (Ad-IFN) demonstrated effectiveness if provided 215 
following the third day of infection.[32] Seven of eight NHPs survived 216 
challenge with signs of mild disease. In a further design to test for an 217 
extension of the potential treatment window, NHPs were treated with Ad-IFN 218 
24 hours after challenge and ZMAb at 96 hours after challenge. Two of four 219 




The delayed administration of MB-003, manufactured in the tobacco plant 221 
Nicotiana benthamiana, was investigated for efficacy in NHPs.[30] Treatment 222 
was initiated at 120 hours after infection with EBOV, with further 223 
administration of MB-003 at 170 and 250 hours post exposure. Only 3 of 7 224 
NHPs survived, and all controls died.  225 
 226 
3.3 Other antibody based therapies 227 
The phosphatidylserine-targeting antibody (PGN401, bavituximab), an 228 
antibody previously demonstrated to have broad-spectrum antiviral activity, 229 
was shown in an in vitro trial to bind and recognise Ebola virus and Ebola 230 
virus infected cells.[33] This may also be a future treatment modality.  231 
The above studies may be limited in their generalisability to human subjects. 232 
The cohort numbers were low, which would also limit the power to detect rare 233 
adverse outcomes of treatment administration.  234 
 235 
4.0 Drugs and small molecules: 236 
4.1 Favipiravir: 237 
The pyrazinecarboxamide derivative T-705 (favipiravir) is licensed in Japan 238 
for the treatment of influenza not responding to conventional therapies.[34] It 239 
has antiviral activity against other negative stranded RNA viruses, and has 240 
been used in the European centres that treated EVD in the last outbreak 241 
(Table-1). It induced rapid Ebola viral clearance in a rodent model when 242 
administered as late as day 6 following inoculation with Ebola virus, in 243 




Results from the JIKI trial in Guinea led by the French Institute of Health and 245 
Medical Research (INSERM) suggest a non-significant lower mortality in 246 
those with low viral loads as indicated by an EBOV RT-PCR cycle to threshold 247 
(CT) of > 20 (20% vs 30% in historic controls) but not in those with high viral 248 
loads (CT<20), with a 91% mortality rate in those treated with favipiravir vs 249 
85% in historic controls.[35] The anti-EVD regimen used in adults was 6,000 250 
mg on day 0, followed by 2,400 mg/d from day 1 to day 9, whereas doses in 251 
children were adjusted to body weight [36].  252 
4.2 Phosphorodiamidate morpholino oligomers and small interfering RNAs:  253 
Molecules such as phosphorodiamidate morpholino oligomers (PMOs), and 254 
small interfering RNAs (siRNAs) have shown efficacy in reducing mortality 255 
when administered to NHPs up to 1 hour after exposure.[37,38] AVI 6002 is a 256 
combination of positively charged phosphorodiamidate morpholino oligomers 257 
(PMOs) designed to target mRNA sequences of VP24 and VP35 in EBOV. It 258 
is currently undergoing phase I clinical trials for EBOV post exposure 259 
treatment. In a study in 2010, AVI-6002 was given intravenously to NHP’s 260 
initiated 30-60min post EBOV exposure at varying doses for up to 14 261 
days.[38] The results of the study demonstrated that 60% of NHPs given 262 
doses of 28mg/kg and 40mg/kg survived with 100 times greater suppression 263 
of mean viral load at the peak of plasma viraemia compared to controls. 264 
Phase I safety trials have shown AVI 6002 to be well tolerated in healthy adult 265 
subjects. TKM-Ebola (formerly Tekmira), is a combination of small interfering 266 
RNAs (siRNAs) formulated in stable nucleic acid lipid particles was developed 267 
by Tekmira Pharmaceutical Corp. The combination of siRNAs targeting the 268 




exposure to EBOV and either 3 or 6 further doses at various intervals 270 
after.[37] Six of the 7 NHPs were protected from EBOV infection with good 271 
tolerance of the drug. During its phase I clinical trial, the U.S Food and Drug 272 
Administration placed a hold on the drug due to safety concerns in regards to 273 
high cytokine levels.[57] This was partially lifted during the outbreak, and 274 
subsequently used in two patients who were treated in the U.S.[58] 275 
Furthermore, it is also being designed to target the Guinea variant of EBOV 276 
and was planned to enter human clinical evaluation in Guinea in emergency 277 
situations.[57] 278 
4.3 Brincidofovir CMX001 279 
CMX001 (Brincidofovir) is a prodrug of cidofovir and is an effective anti-DNA 280 
antiviral medication by inhibiting viral replication secondary to selectively 281 
inhibiting viral DNA polymerases.[39] It is currently undergoing Phase III 282 
clinical trials for use against adenovirus and cytomegalovirus. In vitro tests 283 
have demonstrated efficacy against EBOV although the mechanism of action 284 
is unclear.[39] As a result, Brincidofovir has been used in emergency 285 
situations in patients infected with EBOV and was undergoing Phase II clinical 286 
trials, which were unfortunately halted due to lack of new cases. Brincidofovir 287 
was experimentally used to treat one of the first patients to be transferred to 288 
the U.S.[41]  289 
 290 
4.4 BCX443: 291 
The adenosine analogue, BCX443, when given 48 hours after infection via 292 




nonhuman primate model (Table-1), and could potentially be used for 294 
EVD.[40] BCX4430 inhibits viral RNA polymerase activity indirectly through 295 
non-obligate RNA chain termination. It has shown efficacy in pre-exposure 296 
treatment of EBOV in vitro and in small animal models. In a rodent model, it 297 
demonstrated protection against lethal EBOV challenge receiving BD oral and 298 
IM administration for nine days.[40] BCX4430 is planned for further animal 299 
studies. 300 
5.0 Supportive care 301 
 302 
In the absence of any available directed therapy, the mainstay of 303 
management in EVD has been supportive care. This includes rehydration, 304 
electrolyte replacement, supplemental oxygen, treatment of concomitant 305 
infections, blood products, antipyretics, anti-emetics and anti-diarrhoeal 306 
agents, nutritional support and psychologic care. The level of sophistication of 307 
these interventions varies from basic oral rehydration therapy without 308 
laboratory investigations in the most resource poor settings, through to 309 
invasive fluid, electrolyte and blood product management, mechanical 310 
ventilation, and haemodialysis with full laboratory and radiology support in 311 
intensive care units in developed countries.[42] Even within countries most 312 
affected by EVD, the level of supportive care varied widely.[59,60] Whether 313 
increasing sophistication of supportive care is associated with improved 314 
outcomes is not proven, however, one could not dispute this intuitively. In an 315 
observational study, Cotte et al compared the use of central venous catheters 316 
to peripheral venous catheters for IV access in patients treated at an Ebola 317 




longer line survival times and a higher ratio of volume of fluid infused to that 319 
which was prescribed.[61]  320 
5.1 Authors’ remarks 321 
Case management varied widely due to a variety of reasons. In one major 322 
centre in Liberia, during the peak of the outbreak, the case numbers 323 
overwhelmed the ETC capacity that a decision was made to “close the doors”, 324 
and a palliative approach was followed due to high rates of mortality (reaching 325 
80%).[Box-1] In a different setting, the case load was lower.  Patients with 326 
confirmed EVD were admitted to air conditioned tents, each containing two 327 
beds. Observations included temperature, blood pressure, pulse, oxygen 328 
saturations, respiratory rate, conscious state (AVPU) and level of hydration. 329 
Frequency of observation was between 12th hourly up to 4th hourly or more 330 
frequently, depending on the stage of disease. Fluid balance was recorded, 331 
and urinary catheterisation and rectal tubes (Flexiseal Faecal Management 332 
System) were utilised as needed. Closed circuit cameras allowed continuous 333 
remote visual observation of patients from the staff station outside the ‘red 334 
zone’. Peripheral venous access was established when necessary for 335 
intravenous hydration; central venous access was also utilised for patients 336 
with advanced disease. Ultrasonography was utilised to aid placement of 337 
central venous catheters, and also to assess fluid volume status by observing 338 
inferior vena cava filling. 339 
Point of care pathology testing was utilised within the red zone, using iSTAT™ 340 
devices (analytes tested included sodium, potassium, chloride, ionised 341 




anion gap, pH, PCO2, pO2, lactate, base excess, prothrombin time, INR), 343 
glucometers, and immunochromographic testing for malaria and beta-HCG. 344 
An onsite laboratory performed PCR testing for Ebola virus, as well as rapid 345 
diagnostic tests for Dengue and HIV. In the laboratory, biochemistry testing 346 
was available using the Piccolo™ platform. Analytes assayed on the 347 
Piccolo™ included albumin, urea, calcium, creatinine, glucose, potassium, 348 
sodium, amylase, alanine transaminase, aspartate transaminate, creatinine 349 
kinase, C-reactive protein, bilirubin, lactate, chloride, magnesium, phosphate 350 
and bicarbonate). Haemtology testing was performed on the Hemochron™ 351 
platform and included a full blood count with white cell differential and 352 
coagulation testing. Blood cultures were performed using the BacT/Alert™ 353 
system. The Biofire filmarray™ platform was also utilised for multiplex PCR 354 
testing of respiratory and faecal pathogens, and to detect bacteria from 355 
positive blood cultures. 356 
Pathology testing was performed at least daily in the initial phase of 357 
management, and as required in the convalescent phase. In advanced 358 
disease point of care testing in the red zone was utilised as clinically 359 
necessary for more frequent pathology monitoring.  360 
 361 
Box 1- Tips in resource limited settings 
• Early administration of anti-emetics and anti-diarrhoeal agents 
• Test and treat concurrent infections such as malaria 
• Healthcare worker training and education in principles and practice of 





• Dedicated staff health clinics given higher mortality rates among 
healthcare workers. [62] 
• Early involvement of patients and their carers with ongoing education 
and psychologic care 
• Establish a survivor network for potential training and recruitment  
• Use of technology and minimisation of paper work: example, mobile 
phones and dedicated computers 
• Early coordination between all actors    
 362 
5.2 Mental health 363 
 364 
In our experience, psychosocial support and health promotion (PSHP) are 365 
integral to the care of patients with EVD. In West Africa, many ETCs were 366 
supported by dedicated PSHP teams, responsible for counselling relatives of 367 
those admitted with EVD, coordinating “fence line” visits, linking up family 368 
members admitted to different ETCs, coordinating safe and dignified burials 369 
and allowing family members the possibility of viewing the face of the 370 
deceased, across the fence line separating red zone from the ETC boundary. 371 
PSHP personnel were critical in facilitating access to social support programs 372 
for survivors (food packages, survivor clinics, survivor networks) and providing 373 
education and counselling, including safe sexual practices, in EVD survivors. 374 
They provided an essential point of contact for many survivors who 375 





Mental health of healthcare workers (HCWs) must also not be neglected. 378 
Many returning volunteers experienced stigmatisation. The names of those 379 
HCWs who contracted the illness were publicised.[63] Employers could play a 380 
role in mitigating the sensationalism driven by media by counseling families 381 
prior to an individual’s return. 382 
 383 
6.0 Follow-up 384 
 385 
With around 10,000 survivors of this disease now across West Africa, there is 386 
an increasing demand for the medical management of complications related 387 
to EVD in this survivor cohort. Most notably ocular complications, chronic pain 388 
– especially arthralgias, cognitive, post traumatic stress syndrome and 389 
hearing deficits.[64] The emerging knowledge regarding immune privileged 390 
sites (e.g, eye, semen, cerebrospinal fluid) where the virus can remain 391 
sequestered, highlights the importance of ongoing follow-up and monitoring of 392 
these patients for late effects.[65] Such clinics are now being established in 393 
countries that have experienced high and intense transmission. 394 
 395 
7.0 Discussion: 396 
 397 
To date there are numerous therapeutic options that have been trialled 398 
against EVD, however, data remain scarce to fully recommend any particular 399 
therapy. Management of EBOV infection must emphasize a holistic approach 400 
that includes symptomatic control and takes into consideration the 401 





There is evidence that current vaccines might have the potential to halt an 404 
outbreak, if a ring vaccination strategy is followed.[10] Both candidate 405 
vaccines seem to be well tolerated, however,  we still do not have data on the 406 
duration of their protection or safety in subjects with underlying disease or 407 
medical conditions. There are also no data regarding their safety in paediatric 408 
or pregnant populations. 409 
 410 
Supportive strategies and blood products have been commonly used, and 411 
there is accumulating evidence towards their benefit.[61] Intravenous (IV) fluid 412 
and electrolyte replacement are potentially challenging in certain contexts due 413 
to the lack of infrastructure for sharps management. Their use could be 414 
gradually introduced depending on the capacity of the ETC. EVD patients can 415 
experience difficulties with absconding, denial and combativeness and it is not 416 
uncommon for patients to remove their lines, especially when not observed.  417 
 418 
Other clinical supportive measures can include the use of antipyretics and 419 
anxiolytics for symptom control when needed. Identifying and treating 420 
concurrent infections such as malaria was shown to reduce mortality.[54] 421 
 422 
The orally administered therapeutics seem promising, especially if given early 423 
when the viral load is still low. [35] Concomitant administration of anti-emetics 424 
might be essential. Given the nature of increased volume losses in EVD, 425 
absorption of oral medications might become an issue. To date there are no 426 





8.0 Conclusion: 429 
A number of treatment strategies for EBOV infection, available for some years 430 
remain in the research pipeline. It took this calamitous outbreak to mobilise 431 
resources to move some of them along, but it was too late. The challenging 432 
local conditions and absence of working health infrastructures further 433 
compounded the initiation of clinical trials. Conducting investigations in 434 
outbreak settings will remain a source of debate and ethical dilemmas, 435 
especially in suspicious communities and when engaging care givers 436 
(individuals and government and non-government organisations) unfamiliar 437 
with the conduct of trials, randomization, placebos and the like. The success 438 
of any trial or public health intervention should engage the expertise of cultural 439 
anthropologists. Multidisciplinary collaboration, and delivering health services 440 
at a community level in the future will establish trust, capacity building, and 441 
improve response.  442 
Clinics to follow-up on the survivors to establish the natural history of EVD 443 
and its long term sequelae is an apparently straight forward opportunity for us 444 
to learn.  445 
It is to the credit of WHO to establish a research and development blueprint 446 
for action to prevent epidemics by accelerating availability of vaccines, 447 
effective tests, and medicines at a large scale. [66] Indeed, there is a pipeline 448 
of interesting molecules that potentially could target EBOV.[69] We hope this 449 
will be a significant effort towards an evolving leadership in emergency 450 




investigation following the outbreak has created an opportunity for WHO “to 452 
re-establish its pre-eminence as the guardian of global public health”.[67]  453 
It remains unfortunate that an outbreak involving 28,000 people over more 454 
than a year has passed and the opportunity to evaluate so many putative 455 
therapeutics has been missed. While some therapeutics were used on human 456 
subjects for the first time, we still cannot make conclusions on their safety or 457 
effectiveness. Clinicians and outbreak responders look forward to the day that 458 
well designed and practical clinical trials can be seamlessly rolled out in 459 
parallel with clinical efforts. 460 
 461 
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Table-1: Experimental treatment approaches evaluated for efficacy against Ebola virus disease in mammals 
Approach Target/mechanism of action Demonstrated Efficacy Comments Ref. 
  Rodent NHP Human   
Vaccines 
Plasmid DNA based vaccine 
VRC-EBODNA023-00-VP 
DNA immunisation with boosting adenoviral 
vector  
-- Y Phase I (Uganda) Process takes 6 months to provide protection in NHP 37 
Accelerated vaccine of plasmid DNA 
based vaccine: ChAd-EBOV, Ad5-
EBOV, cAd3-EBOV (GSK) and  
Ad26 and MVA-EBOV (J&J) 
Adenoviral vector delivers DNA encoding 
Ebola GP 
 









Phase I (UK, U.S, China, Mali, 
Uganda, Switzerland)  
Phase II/III*: Liberia 
Phase I*: UK, II/III* US 
Process takes 28 days to provide pre-exposure protection in NHP. Potential for 






rGP nanoparticle (Novavax)  
 
Recombinant Ebola GP admistered with a 
saponin based adjuvant (Matrix-M) 
-- -- Phase I: Australia Requires 2 injections 48 
rVSV-EBOV (Merck), rVSV∆G-EBOV VSV delivers Antigen  
 
-- Y Phase I (Kenya, U.S, 
Switzerland) 
STRIVE: Phase II/III Randomized 
trial in HCWs (Sierra Leone), 
PREVAIL: Phase II (Liberia). Ca 
Suffit: Phase III (Guinea) 
Up to thirty minutes post infection (protection against Ebola -50%, Marburg 
100%) 33% protection after 48 hrs, in NHP 
Geneva phase I trial halted for safety concerns. Less side effects with the newer 
strains. 
Potentially could provide protection after 6 days of vaccinations in humans. No 






Antibody based therapies  
IgG/IgM from convalescent patients Virus neutralisation -- -- Case series, INTERCEPT Phase 
I and Phase II/III (Guinea, Sierra 
Leone, Liberia) 
Widely used during 2014-15 outbreak. No significant mortality benefit in 99 
transfused patients. Two consecutive transfusions of 200-250ml plasma from 
separate concalescent donors 
26,28 
Purified IgG As above -- Y Y 48 hrs protection post infection (100%) in NPH 49 
Cocktail of 3x mouse monoclonal 
antibodies-ZMab 
Targets GP to neutralize the virus (m1H3, 
m2G4, m4G7) 
-- Y Cases 100% effective at 24 hrs 50% @ 48 hrs 31 
Cocktail combined with adenovirus 
vectored interferon-alpha 
As above -- Y -- 72 hrs post infection 75-100%  32 
Cocktail of 3x humanised monoclonal 
antibodies (MB-003)  
ZMapp and MIL-77 (China) 
(c13C6, h13F9, c6D8) 
 
A combination of chimeric mAB c13C6 from 
MB-003 and 2 chimeric mABs (c2G4 and 
c4G7) from ZMab. MIL-77 is produced by 









Cases, Phase I/II trial (multi-
centre) Liberia, Sierra Leone, 
U.S 
Phase I* 
Protection 100% at 1 hr, 67% at 24/48 hrs. 43% survival at 120 hrs post 
infection and development of viraemia and fever in NHP.  







Drugs or small molecules 
TKM-Ebola Tekmira Small interfering RNA cocktail against VP24, 
VP35, and L protein. Encapsulated in stable 
nucleic acid lipid particles (SNALP) 
-- Y Phase I-suspended (partial lift by 
FDA). Phase II: Sierra Leone 
Cases 
IV preparation 100% protection 30 mins post exposure in NHP. Phase II trial 
halted in Sierra Leone. 7 daily infusions: Day1: 0.3mg/Kg, Day2: 0.4mg/Kg, then 
Days3-7: 0.5mg/Kg 
37 
PMOs (AVI-6002) Blocks mRNA transcription -- Y Phase I PEP 62.5% protection within 30 mins in NHP 38 
Favipiravir Pyrazine carboxamide derivative. Selective 
inhibition of viral RNA dependent RNA 
polymerase.  
Y -- Cases 
Phase III (U.S) Licensed in 
Japan for flu. JIKI Phase II trial in 
Guinea 
Rapid viral clearance, used up to day 6 post infection- mice. 
Received by most European cases. Preliminary results from JIKI trial indicate 
effectiveness in cases with low viral load. Day0: 6000mg then Days1-9: 
2400mg. Activity being studied in semen NCT02739477  
34,35 
36 
Brincidofovir (CMX001) Nucleotide analogue. Broad spectrum 
antiviral.  
-- -- Cases 
Phase II (halted in January 2015) 
Developed for CMV, BK viruses. Trial in Liberia halted due to reduction in new 
cases. Loading dose: 200mg then 100mg twice weekly for total of 5 doses 
40,41 
BCX4430 Adenosine analogue (PO/IM). Incorporation 
into viral RNA causing chain termination 
-- Y -- 100% protection of NHP at 48 hrs post infection (Marburg virus), also thought to 
have anti-EVD activity. 
 
32, 39 
PO: oral route, IM: Intramuscular route, NHP: Non-human primates, GP: Glycoprotein, VP: Viral protein, VSV: Vesicular stomatitis virus, CHO: Chinese Hamster Ovarian cells mAB: monoclonal antibodies PMOs: Phosphorodiamidate morpholino oligomers, PEP: Post-exposure 
prophylaxis, FDA: Food and drug agency, MVA: Modified Vaccinia Ankara, GSK:GlaxoSmithKline, J&J: Johnson & Johnson,  
*Ongoing trials as per http://clinicaltrials.gov (at the time of writing) 
Note: Military vaccines (Russia, U.S.A and China) were not included in the table given unavailability of publications in scientific journals. 
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